Pharmaceutical Industry
Kenvue maps out hundreds of layoffs as service pact with J&J winds down - FiercePharma
Euro Convergence: Experts seek 'future proof' pharma legislation as EU elections nears - Regulatory Focus
How sham patents are hurting the pharma industry - Pharmaceutical Technology
Lab to plant: Scaling up API processes with Dr. James Mencel's guidance - News-Medical.Net
The Quest for Greater Channel Visibility in Pharma - Pharmaceutical Executive
Pharma Co. Loses Discovery Appeal Over Protection of Manufacturing Process | New Jersey Law Journal - Law.com
The New Bespak: Championing Sustainability With Chris Hirst - Contract Pharma
Deep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings) - Markets Insider
Drugs Licensed
No Korea-Originated New Drugs Approved Domestically In 2023 - Pink Sheet
Novel Drug Approvals for 2020 - FDA.gov
Clinical Trials Underway for Cancer Drugs Licensed by Georgia State University - Georgia State University News
Metsera comes out of stealth with $290 million for obesity drugs - STAT
Identification of FDA-approved drugs that induce heart regeneration in mammals - Nature.com
Purdue researchers test previously approved FDA drugs to treat Lowe syndrome - Purdue University
Woman faces charges for selling weight loss drugs on TikTok without license - News 12 Westchester
Biden Administration to Reschedule Cannabis Under the Controlled Substances Act – AZ Public Health Association - AZ Public Health Association
FAQs on Prescription Drug Importation - KFF
Drugs Patents
How sham patents are hurting the pharma industry - Pharmaceutical Technology
FTC Targets 'Junk' Patent Listings on Ozempic and Other Drugs - The Wall Street Journal
FTC Warns 'Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How - Forbes
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition - ABC News
AHF • AHF Backs FTC Challenge to Big Pharma Junk Patents - AIDS Healthcare Foundation
FTC targets Novo's Ozempic among 300-plus 'junk' patents - FiercePharma
$52.6 Billion: Extra Cost to Consumers of Add-On Drug Patents - UCLA
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic - CNBC
Teva targets Indian pharma firm over inhaler patents - Life Sciences Intellectual Property Review
Drugs Generics
Office of Generic Drugs 2023 Annual Report - FDA.gov
FDA exploring model master files to expedite generic drug development - Regulatory Focus
Shortages of generic drugs can't be blamed solely on group purchasing organizations - STAT
FTC - HHS.gov
California moves to cut medicine prices with novel deal on opioid overdose drugs - Financial Times
Scant drug ingredients linked to US generic-drug shortages in first 2 COVID years - University of Minnesota Twin Cities
Bankrupt generic drug factory gets a second chance under new ownership : Shots - Health News - NPR
White House Plan To Curb Drug Shortages Doesn't Address Generics' Quality - Forbes
Generic and Biosimilar Medications - National MS Society
FDA Food and Drug Administration
Counterfeit Version of Botox Found in Multiple States - FDA.gov
Updates on Highly Pathogenic Avian Influenza (HPAI) - FDA.gov
US FDA panel to discuss first psychedelic-assisted PTSD treatment next month - Reuters
Palmer Candy Company Recalls White Confectionary Products Because of Possible Health Risk - FDA.gov
Life Finds A Way: The FDA Releases Draft Guidance for Labeling and Advertising Biological and Biosimilar Products - Crowell & Moring LLP
Minority Health and Health Equity - FDA.gov
FDA to Hold Webinar on Agricultural Water Final Rule - Food Safety Magazine
FDA Publishes Final Rule to Enhance the Safety of Agricultural Water - FDA.gov
Chairs Rodgers and Guthrie Announce Health Subcommittee Hearing with Key FDA Center Directors - Energy and Commerce Committee
Pharmaceutical Companies
Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development - FiercePharma
Teva Pharmaceutical Industries (NYSE:TEVA) shareholders have earned a 54% return over the last year - Yahoo Finance
How sham patents are hurting the pharma industry - Pharmaceutical Technology
What innovations are reshaping the pharma services sector? - BioPharma-Reporter.com
Importance of Bilateral III for Switzerland as a pharma location - The Pharma Letter
Amneal resolves opioid lawsuits with $272.5M settlement - FiercePharma
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs - The New York Times
U.S. drugmakers lower U.S. taxes by shifting profits to overseas subsidiaries : Shots - Health News - NPR
Top 20 pharma companies by 2023 revenue - FiercePharma
Retail Pharmacies
Eco-friendly initiatives help retail pharmacies save costs and appeal to consumers - Wolters Kluwer
NACDS applauds enactment of Iowa bill supporting patients' access to essential pharmacist services - Drug Store News
How retail pharmacies can transform clinical trials - EY
Another drugstore chain files for Chapter 11 bankruptcy - TheStreet
Military Pharmacies Restored to Full Operations After Change Healthcare Cyberattack - TRICARE Newsroom
UHS pharmacy services are open to the public - United Health Services
Healthcare Insights: America's Retail Pharmacies - Patients and Pharmacists in Crisis - Cornell University | ILR School
Amazon, CVS, Walgreens And Walmart Push To Let Pharmacists Prescribe Drugs - Forbes
Why CVS’ Oak Street is opening retail clinics as others shutter - Modern Healthcare
Drug Marketing
Endo Health Solutions ordered to pay $1.5 billion for drug marketing - The Philadelphia Inquirer
Pfizer to establish a direct-to-consumer online platform - FiercePharma
The world's broken market for medicines - Financial Times
Biden-Harris Administration Proposes to Protect People with Medicare Advantage and Prescription Drug Coverage ... - HHS.gov
Luke Greenwalt of IQVIA on Obesity Drug Market | Asembia 2024 - Managed Healthcare Executive
Global pharmaceutical industry - statistics & facts - Statista
Ransomware hack hits prescription drug market, inconveniencing millions - The Washington Post
EU Drug Market: Heroin and other opioids — In-depth analysis - European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Amgen wants in on the booming weight loss drug market — and it's taking a different approach - CNBC